Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)

NCT04637594 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT04637594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04637594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 27, 2022
Completion date
September 30, 2030
Enrollment
3 (actual)
Sites
377

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced bladder urothelial carcinoma, locally advanced renal pelvis urothelial carcinoma, locally advanced ureter urothelial carcinoma, locally advanced urethral urothelial carcinoma, locally advanced urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, metastatic urothelial carcinoma